Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
2026-10-23 13:55
•Adria Cimino •The Motley Fool
••• •• Axe Cap view
Moderna’s Volatile Dip: Not a Clear Buy for SA Investors
Moderna’s share price slid sharply despite positive cancer vaccine results, raising questions about buying the dip from a South African perspective.
Moderna’s 17% drop following a leaked clinical trial might look like an opportunity at first glance, especially after an eye-popping 500% rally this year. But this isn’t your typical buying moment. The biotech remains highly volatile, reacting sharply to every clinical update — something that South African investors don’t want to face lightly, especially given no direct JSE equivalent exists. From an FX angle, a weakening rand against the dollar could amplify losses when translating these global gains home. Instead of chasing this rollercoaster, look to more stable local plays. Merck’s partnership with Moderna is interesting, but it’s Merck’s consistent execution in oncology that earns it a strong nod. SA banks like Standard Bank or FirstRand, on the other hand, provide less excitement but more predictability in rand terms. If Moderna’s shares shoot back up on good data, a rand likely weaker under inflationary pressure may eat into returns. This story underscores why global biotech volatility doesn’t always translate into clear local opportunities. this is just our opinion and not financial advice
Avoid buying Moderna at this stage due to volatility and currency risk. Instead, consider trimming exposure to highly priced global tech and focusing on stable JSE counters like Standard Bank or FirstRand, which offer steadier rand-linked returns.
- MRNA
- USD/ZAR
- Standard Bank
- FirstRand
- Further negative clinical trial updates could push Moderna lower
- Rand volatility may amplify losses on USD-denominated assets
6/10
Moderna stock dropped 17% after leaked data from its phase 3 cancer vaccine trial, despite the data showing positive results (42% reduction in recurrence/death risk for melanoma patients). The stock has surged over 500% this year and trades at $200, well above Wall Street's $135 price target. While the dip may present a buying opportunity for long-term investors, the stock remains volatile and sensitive to clinical trial announcements.
Our take is based on reporting first published by The Motley Fool.